Skip to main content

Table 2 Efficacy and safety outcomes of tocilizumab 8 mg/kg monotherapy and combination therapy comprising tocilizumab and a conventional synthetic disease modifying anti-rheumatic drug

From: Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials

  Meta-analysis Sensitivity analysesa
Outcome measures RR 95 % CI P RR 95 % CI P
TCZCOMBI vs. TCZMONO
 DAS28 < 2.6 1.21 1.09, 1.36 <0.001 1.20 1.07, 1.34 0.002
 ACR20 1.05 0.99, 1.12 0.11 1.05 0.98, 1.11 0.17
 ACR50 1.14 1.03, 1.26 0.008 1.13 1.02, 1.25 0.02
 ACR70 1.19 0.94, 1.51 0.14 1.12 0.95, 1.33 0.19
 AEs 1.08 0.97, 1.21 0.17 1.09 0.86, 1.38 0.48
 SAEs 1.40 1.03, 1.92 0.03 1.34 0.79, 2.27 0.27
TCZCOMBI vs. csDMARD
 DAS28 < 2.6 8.77 4.10, 18.75 <0.001 10.39 4.38, 24.65 <0.001
 ACR20 2.10 1.48, 2.99 <0.001 2.15 1.45, 3.19 <0.001
 ACR50 3.00 1.80, 4.99 <0.001 3.24 1.82, 5.78 <0.001
 ACR70 5.32 2.31, 12.25 <0.001 6.23 2.29, 16.93 <0.001
 AEs 1.12 1.06, 1.18 <0.001 1.14 1.07, 1.20 <0.001
 SAEs 1.21 0.91, 1.60 0.19 1.13 0.80, 1.60 0.48
TCZMONO vs. csDMARD
 DAS28 < 2.6 3.95 2.23, 7.00 <0.001 4.50 2.34, 8.64 <0.001
 ACR20 1.68 1.21, 2.32 0.002 1.71 1.18, 2.48 0.005
 ACR50 1.87 1.19, 2.95 0.007 2.01 1.18, 3.42 0.01
 ACR70 2.11 1.18, 3.78 0.01 2.49 1.29, 4.81 0.007
 AEs 1.08 1.01, 1.15 0.03 1.13 0.92, 1.39 0.24
 SAEs 1.21 0.87, 1.69 0.26 1.37 0.64, 2.93 0.42
  1. aThe CHARISMA study was excluded from all meta-analyses; the FUNCTION study was excluded from all meta-analyses of safety outcomes (adverse events (AEs) and serious AEs (SAEs)); the SAMURAI study was excluded from meta-analyses of the safety of tocilizumab monotherapy (TCZMONO) vs. a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD); the SURPRISE study was excluded (from meta-analyses of the safety of tocilizumab combination therapy (TCZCOMBI) vs. TCZMONO. RR relative risk, CI confidence interval, DAS28 Disease Activity Score in 28 joints, ACR American college of Rheumatology, AEs adverse events, SAEs serious AEs